Medical Device Marketing Authorization (MDMA) is the approval granted by the Saudi Food and Drug Authority (SFDA) that allows a medical device or in vitro diagnostic medical device to be placed on the Saudi market. For manufacturers, obtaining MDMA is not the end of the regulatory journey. Authorization must be maintained throughout the product lifecycle.
The SFDA MDMA renewal variation process becomes important when an authorization is nearing expiry, when product information changes or when technical, administrative or regulatory details need to be updated. If these activities are not managed on time, manufacturers may face interruptions in market access, delays in importing products or questions during regulatory review.
This guide explains the renewal, variation and amendment process in clear terms for medical device manufacturers, Saudi Authorized Representatives and regulatory affairs teams working with SFDA requirements.
For a broader overview of initial authorization, classification and submission expectations, OMC Medical’s guide to SFDA medical device registration and MDMA in Saudi Arabia is a useful starting point.
Ready to Streamline Your Regulatory Compliance?
Join hundreds of companies who trust OMC Medical for their regulatory needs. Get expert guidance and ensure compliance across all markets.
Call Now +44 208 066 7260What Is SFDA MDMA Renewal?
SFDA MDMA renewal is the process of maintaining an existing Medical Device Marketing Authorization so that the device can continue to be legally marketed in Saudi Arabia. Renewal helps SFDA confirm that the device, manufacturer and supporting documentation remain valid, current and aligned with applicable regulatory requirements.
Manufacturers should monitor the validity of each MDMA carefully. Renewal should be planned before expiry, not after authorization has lapsed. An expired authorization can create avoidable commercial and compliance risks, including potential disruption to importation, sales or tender participation.
Renewal is also an opportunity to verify that regulatory information has not become outdated. This may include the manufacturer’s legal name and address, device details, certificates, declaration of conformity, technical documentation, labeling and Instructions for Use (IFU). If any of this information has changed, the manufacturer may need to determine whether a renewal alone is sufficient or whether a variation or amendment is also required.
Where a foreign manufacturer relies on a Saudi Authorized Representative, the AR arrangement must also remain active and compliant. If the AR license, mandate or related information changes, this can affect the MDMA record and may need to be addressed before or during the renewal process. Manufacturers managing AR obligations can review OMC Medical’s article on Saudi AR license renewal fees and process for medical devices for related context.
The key point is simple: MDMA renewal is not just an administrative formality. It is part of maintaining continuous regulatory compliance and market access in Saudi Arabia.
SFDA MDMA Renewal Variation Requirements
SFDA MDMA renewal variation requirements may differ depending on the device type, risk classification, product history and the nature of any changes since the original authorization. Manufacturers should always verify the latest applicable SFDA guidance before submitting.
During renewal or variation preparation, the following information may need to be reviewed or updated:
Product and manufacturer details: Confirm the authorized device name, model numbers, catalogue numbers, legal manufacturer details and manufacturing site information.
Regulatory certificates and conformity documents: Review the validity and accuracy of certificates, declarations of conformity, quality management system evidence and other supporting approvals.
Authorized Representative information: Check that the Saudi Authorized Representative details, mandate and related regulatory records remain valid.
Labeling and IFU: Ensure labels, packaging text, symbols, warnings, precautions and Instructions for Use match the authorized device and current regulatory expectations.
Technical documentation: Confirm that device descriptions, design information, risk management files, clinical or performance data and verification evidence are up to date.
Safety and post-market information: Review complaints, adverse events, field safety corrective actions, vigilance reports and post-market surveillance data where applicable.
If the renewal review identifies changes, the manufacturer should not assume they can be silently included without assessment. Each change should be evaluated to determine whether it is significant, non-significant or suitable for an amendment pathway.
MDMA Variations: Significant vs Non-Significant Changes
An MDMA variation in Saudi Arabia is generally required when information linked to an authorized medical device changes after approval. The regulatory pathway depends on the impact of the change. Some changes may affect safety, performance or intended use, while others may be administrative or low impact.
A structured change control process is essential. The manufacturer should document what changed, why it changed, which products are affected and whether the change has any impact on conformity, risk, clinical or performance evidence, labeling or user safety.
Significant Changes
Significant changes are changes that may affect the safety, performance, intended purpose, design, manufacturing process or other important characteristics of the device. These changes usually require formal regulatory assessment before implementation in the Saudi market.
Examples may include changes to the intended use, indications, contraindications, critical design features, materials that contact the patient, sterilization method, manufacturing site or device specifications that affect performance. For software-based devices, changes to algorithms, clinical functionality or risk controls may also require careful evaluation.
The exact categorization should be based on current SFDA requirements and the manufacturer’s documented regulatory assessment. If a change could affect patient safety, device performance or conformity evidence, it should be treated cautiously.
Non-Significant Changes
Non-significant changes are generally lower-impact updates that do not alter the intended use, safety profile, performance claims or core technical characteristics of the device. These may follow a different notification or administrative pathway depending on SFDA rules.
Examples may include certain administrative updates, formatting changes to documentation, minor labeling corrections that do not affect safe use or updates to contact details. However, even apparently minor changes should be assessed and documented. A change that looks administrative at first may still have regulatory impact if it affects traceability, instructions, product identification or market authorization records.
Manufacturers should assess every change according to the latest applicable SFDA requirements rather than relying only on internal assumptions.
SFDA Medical Device Amendment Process
The SFDA medical device amendment process may be needed when specific information within an existing MDMA record must be updated. In practice, the terms amendment and variation may overlap in some regulatory discussions, but the correct submission route depends on the type of change and current SFDA process requirements.
Amendments may be needed for changes such as:
Manufacturer information: Legal name, address, contact details or company structure updates.
Device or product details: Product name, model list, catalogue numbers, accessories or device grouping information.
Saudi Authorized Representative: Appointment, replacement or update of AR information.
Manufacturing site: Addition, removal or modification of a manufacturing location.
Labeling or IFU: Updates to packaging, labels, language content, warnings, precautions or user instructions.
Technical documentation: Updated risk management, testing, clinical evaluation, performance evaluation or quality documents.
Device specifications or intended use: Changes to key specifications, indications, patient population, user profile or use environment.
The amendment file should be clear and traceable. SFDA reviewers need to understand the previous authorized information, the proposed update and the justification for the change. Manufacturers should keep internal change control records aligned with the submitted amendment.
SFDA MDMA Renewal Variation Process: Step by Step
A disciplined process helps avoid missing documents, misclassifying changes or submitting incomplete applications. The following steps can be used as a practical framework for the SFDA MDMA renewal variation workflow.
Review the existing MDMA and expiry status: Confirm the authorization number, approved device scope, product list, expiry date and any conditions linked to the existing authorization.
Identify changes to the device or documentation: Compare the approved file with current product, manufacturer, labeling, technical and post-market information.
Assess the regulatory significance of the change: Determine whether each change is significant, non-significant or suitable for an amendment based on current SFDA requirements.
Prepare updated documents: Compile updated certificates, declarations, technical documentation, labeling, IFU, AR documents and post-market information as applicable.
Submit the appropriate renewal, variation or amendment application: Use the relevant SFDA submission pathway and ensure the application scope matches the actual change.
Respond to SFDA queries: Provide clear responses, corrected documents or additional justifications if SFDA requests clarification during review.
Maintain updated records after approval or acceptance: Store the final approved documents, SFDA correspondence and change rationale in the regulatory file.
The process should be integrated with the manufacturer’s quality management system. Regulatory affairs, quality, supply chain and commercial teams should communicate early, especially if product changes may affect Saudi market availability.
SFDA Fees for Medical Devices
SFDA fees for medical devices may depend on the application type, device classification, regulatory pathway and scope of submission. Fees can also change over time, so manufacturers should confirm the latest official SFDA requirements before budgeting or submitting an application.
OMC Medical has a dedicated overview of SFDA fees for medical devices, which can help regulatory teams understand the types of fees that may apply. Specific fee values should always be checked against current SFDA sources before making decisions.
Practical Tips for Managing MDMA Changes
Manufacturers can reduce renewal and variation risks by treating MDMA maintenance as a continuous lifecycle activity rather than a last-minute submission task. The earlier a change is identified, the easier it is to determine whether SFDA action is needed.
A practical approach is to maintain a Saudi-specific regulatory change log. This log should connect each internal change control record to the affected MDMA, device models, documents and market status. It should also record the regulatory assessment, decision rationale, submission date and SFDA outcome.
Labeling control deserves particular attention. Changes to labels or IFU can appear simple, but they may affect user understanding, language requirements, warnings, device identification or traceability. Before releasing updated artwork for Saudi Arabia, regulatory teams should confirm whether an amendment or variation is needed.
Post-market information should also be reviewed before renewal. Complaints, adverse events, recalls, field safety corrective actions and trend data may influence the renewal file or support the continued acceptability of the device. A complete post-market review demonstrates that the manufacturer is actively monitoring device safety and performance.
Finally, manufacturers should keep the Saudi Authorized Representative informed of planned changes. The AR may need to support submissions, maintain local records or communicate with SFDA. Delayed AR involvement can lead to duplicated work or submission delays.
Common Challenges in SFDA MDMA Renewal and Variation
One common challenge is incomplete alignment between the approved MDMA record and the manufacturer’s current global technical file. Product portfolios change over time, and model lists, catalogue numbers, manufacturing sites or certificates may no longer match the original Saudi submission.
Another challenge is unclear change classification. If the manufacturer does not have a documented rationale for treating a change as significant or non-significant, SFDA queries may be harder to answer. A clear assessment matrix and internal approval trail can make the submission more defensible.
Manufacturers also need to manage timing. Renewal, variation and amendment activities may interact with certificate renewals, AR license status, labeling updates or manufacturing transfers. When these activities are handled separately, there is a higher risk of inconsistent information across documents.
A coordinated plan helps ensure that the MDMA file, quality system records, supply chain documentation and Saudi market labeling all tell the same regulatory story.
Conclusion
Managing SFDA MDMA renewal, variation and amendment activities proactively is essential for continued medical device market access in Saudi Arabia. Manufacturers should monitor authorization validity, assess every product or documentation change and keep technical, labeling, post-market and Authorized Representative records current.
A well-managed SFDA MDMA renewal variation process reduces compliance risk, supports smoother SFDA interactions and helps prevent avoidable disruption to Saudi market supply. Regulatory teams should always verify current SFDA requirements before submission and maintain clear records for every decision made during the device lifecycle.
